Liminatus Pharma, Inc. Class A Common Stock (LIMN) - Total Assets
Based on the latest financial reports, Liminatus Pharma, Inc. Class A Common Stock (LIMN) holds total assets worth $1.34 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See LIMN net asset value for net asset value and shareholders' equity analysis.
Liminatus Pharma, Inc. Class A Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's total assets have evolved over time, based on quarterly financial data.
Liminatus Pharma, Inc. Class A Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Liminatus Pharma, Inc. Class A Common Stock's total assets of $1.34 Million consist of 28.7% current assets and 71.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.4% |
| Accounts Receivable | $6.46K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Liminatus Pharma, Inc. Class A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Liminatus Pharma, Inc. Class A Common St market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Liminatus Pharma, Inc. Class A Common Stock's current assets represent 28.7% of total assets in 2024, an increase from 0.2% in 2021.
- Cash Position: Cash and equivalents constituted 28.4% of total assets in 2024, up from 0.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Liminatus Pharma, Inc. Class A Common Stock Competitors by Total Assets
Key competitors of Liminatus Pharma, Inc. Class A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Liminatus Pharma, Inc. Class A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.42 | 0.05 | 0.08 |
| Quick Ratio | 0.42 | 0.05 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.66 Million | $-7.14 Million | $-4.25 Million |
Liminatus Pharma, Inc. Class A Common Stock - Advanced Valuation Insights
This section examines the relationship between Liminatus Pharma, Inc. Class A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.89 |
| Asset Growth Rate (YoY) | -37.2% |
| Total Assets | $2.83 Million |
| Market Capitalization | $5.33 Million USD |
Valuation Analysis
Above Book Valuation: The market values Liminatus Pharma, Inc. Class A Common Stock's assets above their book value (1.89x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Liminatus Pharma, Inc. Class A Common Stock's assets decreased by 37.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Liminatus Pharma, Inc. Class A Common Stock (2021–2024)
The table below shows the annual total assets of Liminatus Pharma, Inc. Class A Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.83 Million | -37.17% |
| 2023-12-31 | $4.50 Million | -70.93% |
| 2022-12-31 | $15.49 Million | -94.40% |
| 2021-12-31 | $276.44 Million | -- |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more